Carmel, Ind. (September 22, 2015) – Nanovis Spine today announced the award of a significant research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). The grant will fund advanced research evaluating the potential of Nanovis’ FortiCoreTM implant technology combined with the Company’s developmental nanotube surface technology to
accelerate the speed and strength of spinal segment stabilization following spinal fusion procedures.
FortiCore’s deeply porous titanium scaffold is a highly differentiated implant.PEEK Optima® by Invibio is injection molded into the scaffold for exceptional integration, while the PEEK center provides the imaging and mechanical properties preferred by surgeons. Nanovis’ nanotube technology forms durable, nanoscale surface features that have demonstrated the ability to improve bone attachment by generating the body’s natural ability to guide healing and cellular responses.
“In today’s healthcare environment, spinal surgeons are always searching for technologies that can help improve the lives of our patients. With an aging patient population increasingly in need of spinal surgery, advanced technologies that can reduce the time it takes to stabilize spinal segments or enable faster recovery times are in high-demand,” said Jean-Jacques Abitbol, M.D., Past-President NASS, Founder California Spine Group, and Co-Investigator on the grant. “Our prior work using Nanovis’ spinal implant technology is being prepared for publication and suggests the deep pores in the titanium scaffold provide considerably better fixation compared to allograft or PEEK implants. Adding customized nanotube surface technology to the implants has significant potential to further improve results.”
“Support from the NIH is highly selective and underscores the potential of Nanovis’ technology,” said Matt Hedrick, Chief Executive Officer, Nanovis. “Our research and development team includes some of the first scientists to discover
implant nanotechnology alongside innovative and highly accomplished spine surgeons working to develop and deliver commercially viable implants that evolve patient care.”
Nanovis’ mission is to lead its selected markets with science-enhanced, life improving technology. Nanovis applies its patented and proprietary technologies to its ever-increasing number of implant platforms. With patents extending well
into the next decade these technologies are expected to fuel growth for years to come. Nanovis’ technology platforms provide differentiated, science-driven advantages to Nanovis’ products that appeal to surgeons and hospital networks attempting to maximize outcomes with the best technology for their patients. Nanovis has three advanced implant technology platforms, the FortiCore implant family; a PEEK spinal implant deeply porous titanium scaffold endplates which
has entered the U.S. market, and an advanced nanotechnology platform under development, and an innovative anti-colonization and antimicrobial implant platform also under development.